Meeting Niche Market Needs
Improving Patients’ Quality of Life
Governance and Growth Through Innovation
Where Experience Meets Expertise
CMP Pharma, Inc Announces That CaroSpir®, The First And Only FDA-Approved Spironolactone Oral Suspension, Is Now Available
CMP Pharma today announced that CaroSpir® (Spironolactone Oral Suspension, 25 mg/5 mL), the first and only FDA-approved oral liquid dosage form of the potassium-sparing diuretic spironolactone, is now available. CaroSpir was approved by the FDA on August 4, 2017 and is now available through normal retail distribution.